Pertussis Market Shows Strong Future Potential with Increasing Industry Investments by 2036 - DelveInsight

DelveInsight's "Pertussis Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Pertussis, historical and forecasted epidemiology as well as the Pertussis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Pertussis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pertussis Market Forecast
https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Pertussis Market Report:
• The Pertussis market size was valued at approximately USD 4.0 billion in 2025 and is projected to reach around USD 5.0 billion by 2036, growing at a CAGR of 2.7% during the forecast period from 2026 to 2036.
• In February 2026, ILiAD Biotechnologies Secures Oversubscribed USD115M Series B to Advance BPZE1 Pertussis Vaccine Development.
• GSK Reports Q3 2025 Results shows BOOSTRIX Generates USD122M Sales, Supporting Established Vaccines Portfolio Growth.
• In June 2024, ILiAD Biotechnologies announced the selection of Emmes Group, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1. ILiAD and Emmes Group are currently working to finalize the definitive agreement.
• In May 2024, ILiAD Biotechnologies reported that BPZE1 demonstrated positive topline interim results in the SUPER (Stand Up to Pertussis) school-age trial conducted in 366 participants in the United Kingdom, Australia and Costa Rica.
• The total market size in the US for pertussis was estimated to be nearly USD 3,200 million in 2025, which is expected to increase due to the launch of emerging therapies and label expansion of current therapies.
• The market share of Spain for pertussis was found to be the lowest in 2025.
• In the 7MM, PENTACEL leads in market size due to high-volume pediatric use, while BOOSTRIX shows strong growth potential driven by expanding booster and maternal immunization programs.
• In 2025, the US accounted for the highest cases of pertussis i.e., 60% of the total cases in the 7MM.
• Among the 7MM, vaccination coverage for children is reported to be high; in comparison, booster vaccination compliance among adults is reported to be low owing to the fact. With the increasing awareness, the updation of immunization recommendations and the entry of emerging vaccines are expected to increase the vaccination coverage rate.
• As per DelveInsight's estimate, the total Pertussis vaccinated population in the US was approximately 20 million in 2025 and is projected to increase during the forecast period (2026-2036).
• Pertussis infection can lead to complications, particularly pneumonia (lung infection) in infants and older adults. In severe cases, infants may show signs such as poor feeding, irritability and unusual tiredness, while breathing difficulties can progress to respiratory distress.
• Key Pertussis Companies: Sanofi Pasteur, GlaxoSmithKline, Merck, Mitsubishi Tanabe Pharma Corporation, Cansino Bio, ILiAD Biotechnologies, Mitsubishi Tanabe Pharma Corporation, Serum Institute, Bilthoven, VPM, and others
• Key Pertussis Therapies: ADACEL/REPEVAX, BOOSTRIX, VAXELIS, DPT-IPV-Hib (BK-1310/MT-2355), DTcP, BPZE1, BK1310/MT-2355, SIIPL Tdap, and others
• The Pertussis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pertussis pipeline products will significantly revolutionize the Pertussis market dynamics.

Pertussis Overview
Pertussis, also known as whooping cough, is a highly contagious respiratory infection caused by the bacterium Bordetella pertussis. It is characterized by severe coughing fits, often with a "whooping" sound when the person breathes in after coughing. Pertussis can affect people of all ages, but it is particularly severe in infants and young children who have not been fully vaccinated.

Get a Free sample for the Pertussis Market Report
https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pertussis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pertussis Epidemiology Segmentation:
The Pertussis market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Pertussis Vaccination Coverage

Download the report to understand which factors are driving Pertussis epidemiology trends @ Pertussis Epidemiology Forecast
https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pertussis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pertussis market or expected to get launched during the study period. The analysis covers Pertussis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pertussis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pertussis Therapies and Key Companies
• ADACEL/REPEVAX: Sanofi Pasteur
• BOOSTRIX: GlaxosmithKline
• VAXELIS: Merck
• DPT-IPV-Hib (BK-1310/MT-2355): Mitsubishi Tanabe Pharma Corporation
• DTcP: Cansino Bio
• BPZE1: ILiAD Biotechnologies
• BK1310/MT-2355: Mitsubishi Tanabe Pharma Corporation
• SIIPL Tdap: Serum Institute/Bilthoven/VPM

Discover more about therapies set to grab major Pertussis market share @ Pertussis Treatment Market
https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pertussis Market Drivers
• Rising incidence of pertussis outbreaks across both developed and developing countries is increasing demand for effective vaccination and preventive strategies.
• Growing awareness of booster immunization programs for adolescents, adults, and pregnant women is expanding vaccine uptake.
• Government-led vaccination initiatives and immunization campaigns are supporting broader market growth.
• Advancements in vaccine development, including next-generation acellular and combination vaccines, are expected to improve protection and drive adoption.

Pertussis Market Barriers
• Waning immunity associated with current acellular vaccines can reduce long-term protection and impact vaccine effectiveness.
• Vaccine hesitancy and misinformation remain significant challenges in achieving optimal vaccination coverage.
• High costs associated with vaccine development, manufacturing, and distribution may limit accessibility in certain regions.
• Stringent regulatory requirements can delay the approval and commercialization of new vaccine candidates.

Scope of the Pertussis Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pertussis Companies: Sanofi Pasteur, GlaxoSmithKline, Merck, Mitsubishi Tanabe Pharma Corporation, Cansino Bio, ILiAD Biotechnologies, Mitsubishi Tanabe Pharma Corporation, Serum Institute, Bilthoven, VPM, and others
• Key Pertussis Therapies: ADACEL/REPEVAX, BOOSTRIX, VAXELIS, DPT-IPV-Hib (BK-1310/MT-2355), DTcP, BPZE1, BK1310/MT-2355, SIIPL Tdap, and others
• Pertussis Therapeutic Assessment: Pertussis current marketed and Pertussis emerging therapies
• Pertussis Market Dynamics: Pertussis market drivers and Pertussis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pertussis Unmet Needs, KOL's views, Analyst's views, Pertussis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.